Bookmark and Share
SMR000310192 (CID 16193817) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(31)
 
 
Inactive(645)
 
 
Inconclusive(14)
 
 
Unspecified(3)
 
 
Top Targets:
7TM GPCR Srx(22)
 
 
 
Abhydrolase 2(21)
 
 
 
 
7TM GPCR Srsx(16)
 
 
 
G-alpha(10)
 
 
 
 
Peptidase S9(9)
 
 
BioAssay Types:
Screening(424)
 
 
 
 
Confirmatory(194)
 
 
 
 
 
Literature(5)
 
 
BioActivity Types:
Potency(133)
 
 
 
 
 
IC50(42)
 
 
 
 
EC50(7)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 579    Data Row: 693   Total Pages: 14   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID160654496]
0.144Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP [AID651990_2, Type: confirmatory]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
2
[SID160654496]
Average IC50 [LYPLA2] 0.51Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Substrate-based fluorescence-based biochemical determination of kinetic parameters [AID652001, Type: confirmatory]
View
3
[SID24812860]
Potency 10qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) [AID651820, Type: confirmatory]
View
4
[SID24812860]
Potency 12.9953qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
5
[SID24812860]
EC50 50A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen [AID2252, Type: confirmatory]
View
6
[SID92709328]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID652030, Type: other]
View
7
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situ [AID651980, Type: other]
View
8
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro [AID651981, Type: other]
View
9
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID651988, Type: other]
View
10
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivo [AID651985, Type: other]
View
11
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in situ [AID651986, Type: other]
View
12
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess binding mode [AID651987, Type: other]
View
13
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP [AID651990, Type: confirmatory]
View
14
[SID24812860]
Counterscreen for antagonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective antagonists [AID651780, Type: screening]guanine nucleotide-binding protein subunit alpha-15 [Homo sapiens] [gi:156104883]
View
15
[SID24812860]
Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1 [AID1304, Type: screening]neuropeptide Y receptor type 1 [Homo sapiens] [gi:4505445]
View
16
[SID24812860]
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1) [AID624466, Type: screening]trace amine-associated receptor 1 [Homo sapiens] [gi:21264324]
View
17
[SID24812860]
Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2 [AID1359, Type: screening]neuropeptide Y receptor type 2 [Homo sapiens] [gi:4505447]
View
18
[SID24812860]
Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide [AID687016, Type: screening]E3 ubiquitin-protein ligase UHRF1 isoform 1 [Homo sapiens] [gi:115430235]
View
19
[SID24812860]
Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2). [AID2232, Type: screening]lysophospholipase II [Homo sapiens] [gi:4581413]
View
20
[SID24812860]
Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2). [AID2177, Type: screening]lysophospholipase II [Homo sapiens] [gi:4581413]
View
21
[SID24812860]
Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype [AID1531, Type: screening]mitogen-activated protein kinase kinase kinase kinase 2 [Homo sapiens] [gi:22035600]
View
22
[SID92709328]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID652030_2, Type: other]lysophospholipase 2 [Mus musculus] [gi:123122209]
View
23
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivo [AID651985_2, Type: other]lysophospholipase 2 [Mus musculus] [gi:123122209]
View
24
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in situ [AID651986_4, Type: other]lysophospholipase 2 [Mus musculus] [gi:123122209]
View
25
[SID92709328]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition [AID652029, Type: other]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
26
[SID92709328]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID652030_1, Type: other]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
27
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situ [AID651980_1, Type: other]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
28
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID651988_2, Type: other]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
29
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess binding mode [AID651987_2, Type: other]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
30
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in situ [AID651986_2, Type: other]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
31
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro [AID651981_1, Type: other]acyl-protein thioesterase 2 [Mus musculus] [gi:7242156]
View
32
[SID160654496]
Average IC50 [LYPLA2] 0.51Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Substrate-based fluorescence-based biochemical determination of kinetic parameters [AID652001_1, Type: confirmatory]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
33
[SID160654496]
Average IC50 [LYPLA2] Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Substrate-based fluorescence-based biochemical determination of kinetic parameters [AID652001_2, Type: confirmatory]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
34
[SID24812860]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
35
[SID24812860]
Potency 0.2818qHTS for Inhibitors of TGF-b: Cytotox Counterscreen [AID588856, Type: confirmatory]
View
36
[SID160654496]
3Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP [AID651990_1, Type: confirmatory]acyl-protein thioesterase 1 isoform 1 [Homo sapiens] [gi:5453722]
View
37
[SID160654496]
IC50 10Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: fluorescence-based biochemical dose-response assay [AID652003, Type: confirmatory]acyl-protein thioesterase 1 isoform 1 [Homo sapiens] [gi:5453722]
View
38
[SID160654496]
50Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds [AID651991_1, Type: confirmatory]
View
39
[SID160654496]
50Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds [AID651991_2, Type: confirmatory]
View
40
[SID24812860]
Potency qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS [AID720580, Type: confirmatory]67.9K protein [Vaccinia virus] [gi:222762]
View
41
[SID24812860]
Primary HTS Assay for S1P3 Antagonists [AID485, Type: screening]sphingosine 1-phosphate receptor 3 [Homo sapiens] [gi:38788193]
View
42
[SID24812860]
HTS Assay for Peg3 Promoter Inhibitors [AID588405, Type: screening]protein phosphatase 1 regulatory subunit 15A [Rattus norvegicus] [gi:78486550]
View
43
[SID24812860]
Potency qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization [AID1468, Type: confirmatory]Microtubule-associated protein tau [Homo sapiens] [gi:92096784]
View
44
[SID24812860]
IC50 Fluorescence for the identification of compounds that decrease p/CIP protein stability [AID1984, Type: confirmatory]nuclear receptor coactivator 3 [Mus musculus] [gi:118026946]
View
45
[SID24812860]
Potency qHTS for Inhibitors of Polymerase Iota [AID588590, Type: confirmatory]DNA polymerase iota [Homo sapiens] [gi:154350220]
View
46
[SID24812860]
uHTS Fluorescent assay for identification of inhibitors of Apaf-1 [AID489030, Type: screening]Apoptotic peptidase activating factor 1 [Homo sapiens] [gi:187952397]
View
47
[SID24812860]
uHTS Fluorescent assay for identification of activators of Apaf-1 [AID489031, Type: screening]Apoptotic peptidase activating factor 1 [Homo sapiens] [gi:187952397]
View
48
[SID24812860]
Potency VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity [AID2546, Type: confirmatory]nuclear receptor ROR-gamma [Mus musculus] [gi:188536040]
View
49
[SID24812860]
Potency qHTS for inhibitors of ROR gamma transcriptional activity [AID2551, Type: confirmatory]nuclear receptor ROR-gamma [Mus musculus] [gi:188536040]
View
50
[SID24812860]
uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors [AID602141, Type: screening]
View